Logo image of XTNT

XTANT MEDICAL HOLDINGS INC (XTNT) Stock Fundamental Analysis

USA - NYSEARCA:XTNT - US98420P3082 - Common Stock

0.7707 USD
-0.01 (-1.45%)
Last: 10/23/2025, 8:04:00 PM
0.78 USD
+0.01 (+1.21%)
After Hours: 10/23/2025, 8:04:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to XTNT. XTNT was compared to 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of XTNT have multiple concerns. While showing a medium growth rate, XTNT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

In the past year XTNT has reported negative net income.
XTNT had a positive operating cash flow in the past year.
XTNT had negative earnings in 4 of the past 5 years.
XTNT had negative operating cash flow in 4 of the past 5 years.
XTNT Yearly Net Income VS EBIT VS OCF VS FCFXTNT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

XTNT has a better Return On Assets (-4.43%) than 66.32% of its industry peers.
XTNT has a Return On Equity of -9.44%. This is in the better half of the industry: XTNT outperforms 66.32% of its industry peers.
XTNT has a better Return On Invested Capital (0.03%) than 65.26% of its industry peers.
Industry RankSector Rank
ROA -4.43%
ROE -9.44%
ROIC 0.03%
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
XTNT Yearly ROA, ROE, ROICXTNT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

The Operating Margin of XTNT (0.02%) is better than 65.26% of its industry peers.
XTNT has a better Gross Margin (60.16%) than 60.53% of its industry peers.
XTNT's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 0.02%
PM (TTM) N/A
GM 60.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
XTNT Yearly Profit, Operating, Gross MarginsXTNT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XTNT is destroying value.
Compared to 1 year ago, XTNT has more shares outstanding
Compared to 5 years ago, XTNT has more shares outstanding
Compared to 1 year ago, XTNT has a worse debt to assets ratio.
XTNT Yearly Shares OutstandingXTNT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
XTNT Yearly Total Debt VS Total AssetsXTNT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -0.53, we must say that XTNT is in the distress zone and has some risk of bankruptcy.
XTNT has a Altman-Z score of -0.53. This is comparable to the rest of the industry: XTNT outperforms 41.05% of its industry peers.
A Debt/Equity ratio of 0.46 indicates that XTNT is not too dependend on debt financing.
XTNT has a Debt to Equity ratio (0.46) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Altman-Z -0.53
ROIC/WACC0
WACC8.94%
XTNT Yearly LT Debt VS Equity VS FCFXTNT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.47 indicates that XTNT has no problem at all paying its short term obligations.
With a Current ratio value of 2.47, XTNT perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
XTNT has a Quick Ratio of 1.16. This is a normal value and indicates that XTNT is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.16, XTNT is not doing good in the industry: 70.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.47
Quick Ratio 1.16
XTNT Yearly Current Assets VS Current LiabilitesXTNT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

4

3. Growth

3.1 Past

The earnings per share for XTNT have decreased strongly by -100.00% in the last year.
Looking at the last year, XTNT shows a quite strong growth in Revenue. The Revenue has grown by 15.16% in the last year.
Measured over the past years, XTNT shows a quite strong growth in Revenue. The Revenue has been growing by 12.64% on average per year.
EPS 1Y (TTM)-100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
Revenue 1Y (TTM)15.16%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%18.26%

3.2 Future

Based on estimates for the next years, XTNT will show a very strong growth in Earnings Per Share. The EPS will grow by 30.30% on average per year.
Based on estimates for the next years, XTNT will show a small growth in Revenue. The Revenue will grow by 3.31% on average per year.
EPS Next Y108.5%
EPS Next 2Y42.92%
EPS Next 3Y30.31%
EPS Next 5YN/A
Revenue Next Year10.6%
Revenue Next 2Y0.34%
Revenue Next 3Y3.31%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
XTNT Yearly Revenue VS EstimatesXTNT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
XTNT Yearly EPS VS EstimatesXTNT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2023 2024 2025 2026 2027 0 -5 -10 -15 -20

2

4. Valuation

4.1 Price/Earnings Ratio

XTNT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 151.12 indicates a quite expensive valuation of XTNT.
66.32% of the companies in the same industry are more expensive than XTNT, based on the Price/Forward Earnings ratio.
XTNT's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.33.
Industry RankSector Rank
PE N/A
Fwd PE 151.12
XTNT Price Earnings VS Forward Price EarningsXTNT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XTNT indicates a somewhat cheap valuation: XTNT is cheaper than 71.58% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 30.13
XTNT Per share dataXTNT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
XTNT's earnings are expected to grow with 30.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.92%
EPS Next 3Y30.31%

0

5. Dividend

5.1 Amount

XTNT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

XTANT MEDICAL HOLDINGS INC

NYSEARCA:XTNT (10/23/2025, 8:04:00 PM)

After market: 0.78 +0.01 (+1.21%)

0.7707

-0.01 (-1.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners57.12%
Inst Owner Change0%
Ins Owners14.93%
Ins Owner Change-0.26%
Market Cap107.90M
Revenue(TTM)127.77M
Net Income(TTM)-4581000
Analysts85
Price Target1.79 (132.26%)
Short Float %0.06%
Short Ratio0.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)198.04%
Min EPS beat(2)100%
Max EPS beat(2)296.08%
EPS beat(4)2
Avg EPS beat(4)77.12%
Min EPS beat(4)-56.86%
Max EPS beat(4)296.08%
EPS beat(8)3
Avg EPS beat(8)73.86%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)7.07%
Min Revenue beat(2)3.39%
Max Revenue beat(2)10.74%
Revenue beat(4)2
Avg Revenue beat(4)1.19%
Min Revenue beat(4)-6.52%
Max Revenue beat(4)10.74%
Revenue beat(8)6
Avg Revenue beat(8)5.84%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)150%
EPS NY rev (3m)128.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 151.12
P/S 0.84
P/FCF N/A
P/OCF 71.88
P/B 2.22
P/tB 3.2
EV/EBITDA 30.13
EPS(TTM)-0.04
EYN/A
EPS(NY)0.01
Fwd EY0.66%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.01
OCFY1.39%
SpS0.91
BVpS0.35
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.43%
ROE -9.44%
ROCE 0.04%
ROIC 0.03%
ROICexc 0.03%
ROICexgc 0.04%
OM 0.02%
PM (TTM) N/A
GM 60.16%
FCFM N/A
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
F-Score5
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Debt/EBITDA 4.97
Cap/Depr 97.07%
Cap/Sales 3.39%
Interest Coverage 0.01
Cash Conversion 33.42%
Profit Quality N/A
Current Ratio 2.47
Quick Ratio 1.16
Altman-Z -0.53
F-Score5
WACC8.94%
ROIC/WACC0
Cap/Depr(3y)93.26%
Cap/Depr(5y)102.58%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
EPS Next Y108.5%
EPS Next 2Y42.92%
EPS Next 3Y30.31%
EPS Next 5YN/A
Revenue 1Y (TTM)15.16%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%18.26%
Revenue Next Year10.6%
Revenue Next 2Y0.34%
Revenue Next 3Y3.31%
Revenue Next 5YN/A
EBIT growth 1Y100.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year230.8%
EBIT Next 3Y49%
EBIT Next 5YN/A
FCF growth 1Y74.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y116.46%
OCF growth 3YN/A
OCF growth 5YN/A